stocks logo

PLX

Protalix Biotherapeutics Inc
$
1.460
-0.04(-2.667%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.530
Open
1.500
VWAP
--
Vol
455.91K
Mkt Cap
116.23M
Low
1.460
Amount
--
EV/EBITDA(TTM)
16.25
Total Shares
73.32M
EV
96.77M
EV/OCF(TTM)
--
P/S(TTM)
2.05
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
16.64M
-8.65%
--
--
17.72M
-0.64%
--
--
13.49M
+1.37%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Protalix BioTherapeutics, Inc. (PLX) for FY2025, with the revenue forecasts being adjusted by 5.09% over the past three months. During the same period, the stock price has changed by -52.44%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.09%
In Past 3 Month
Stock Price
Go Down
down Image
-52.44%
In Past 3 Month
1 Analyst Rating
up Image
927.40% Upside
Wall Street analysts forecast PLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLX is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image
927.40% Upside
Current: 1.460
sliders
Low
15.00
Averages
15.00
High
15.00
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$10 → $15
2025-02-03
Reason

Valuation Metrics

The current forward P/E ratio for Protalix Biotherapeutics Inc (PLX.A) is 6.25, compared to its 5-year average forward P/E of 0.57. For a more detailed relative valuation and DCF analysis to assess Protalix Biotherapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.57
Current PE
6.25
Overvalued PE
20.69
Undervalued PE
-19.55

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.42
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.33
Undervalued EV/EBITDA
-0.49

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
2.03
Current PS
1.76
Overvalued PS
3.18
Undervalued PS
0.87

Financials

Annual
Quarterly
FY2025Q1
YoY :
+169.82%
10.11M
Total Revenue
FY2025Q1
YoY :
-14.64%
-4.15M
Operating Profit
FY2025Q1
YoY :
-21.24%
-3.62M
Net Income after Tax
FY2025Q1
YoY :
-16.67%
-0.05
EPS - Diluted
FY2025Q1
YoY :
-249.42%
-5.36M
Free Cash Flow
FY2025Q1
YoY :
-37.51%
19.11
Gross Profit Margin - %
FY2025Q1
YoY :
-135.66%
-2.61
FCF Margin - %
FY2025Q1
YoY :
-70.81%
-35.79
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

PLX News & Events

Events Timeline

2025-07-21 (ET)
2025-07-21
06:52:09
Protalix appoints Gilad Mamlok as CFO
select
2025-06-30 (ET)
2025-06-30
07:00:54
Protalix added to Russell 3000, Russell 2000 Indexes
select
2024-12-09 (ET)
2024-12-09
05:35:52
Protalix, Chiesi announce EMA validation of pegunigalsidase Variation Submission
select
Sign Up For More Events

News

5.0
07-21NASDAQ.COM
Protalix BioTherapeutics Names Gilad Mamlok CFO
5.0
07-21Newsfilter
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
5.0
07-21SeekingAlpha
Protalix BioTherapeutics appoints Gilad Mamlok as CFO
Sign Up For More News

FAQ

arrow icon

What is Protalix Biotherapeutics Inc (PLX) stock price today?

The current price of PLX is 1.46 USD — it has decreased -2.67 % in the last trading day.

arrow icon

What is Protalix Biotherapeutics Inc (PLX)'s business?

arrow icon

What is the price predicton of PLX Stock?

arrow icon

What is Protalix Biotherapeutics Inc (PLX)'s revenue for the last quarter?

arrow icon

What is Protalix Biotherapeutics Inc (PLX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Protalix Biotherapeutics Inc (PLX)'s fundamentals?

arrow icon

How many employees does Protalix Biotherapeutics Inc (PLX). have?

arrow icon

What is Protalix Biotherapeutics Inc (PLX) market cap?